A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Public ClinicalTrials.gov record NCT01774851. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
Study identification
- NCT ID
- NCT01774851
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Enrollment
- 84 participants
Conditions and interventions
Conditions
Interventions
- MM-111 Drug
- Paclitaxel Drug
- Trastuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2012
- Primary completion
- Jun 30, 2015
- Completion
- Nov 30, 2015
- Last update posted
- Jun 21, 2017
2013 – 2015
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Los Angeles | California | 90089 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Stanford | California | 94305 | — |
| Not listed | Denver | Colorado | 80218 | — |
| Not listed | Ocala | Florida | 34471 | — |
| Not listed | St. Petersburg | Florida | 33705 | — |
| Not listed | Urbana | Illinois | 61801 | — |
| Not listed | Boston | Massachusetts | 02111 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Las Vegas | Nevada | 89135 | — |
| Not listed | Buffalo | New York | 14263 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Cleveland | Ohio | 44106 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Philadelphia | Pennsylvania | 19111 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01774851, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01774851 live on ClinicalTrials.gov.